Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Relapse Incidence Post Unrelated Allogeneic Stem Cell Transplantation with Post-Transplant Cyclophosphamide (PTCy) Versus Conventional Anti-Graft Versus Host Disease Prophylaxis in Patients with Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Blood (2023) 142 (Supplement 1): 237.

https://doi.org/10.1182/blood-2023-174020

Published: 2023

Journal Articles

Prognostic Factors Impacting Post-Transplant Outcomes in Adult T-Cell Acute Lymphoblastic Leukemia: A Registry-Based Study By the EBMT Acute Leukemia Working Party

Blood (2023) 142 (Supplement 1): 2237.

https://doi.org/10.1182/blood-2023-180686

Published: 2023

Journal Articles

A Multi-Center Retrospective Analysis of Outcomes Post Allogeneic Stem Cell Transplantation in AML Patients with TET2 Mutations: A Study on Behalf of the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Blood (2023) 142 (Supplement 1): 4986.

https://doi.org/10.1182/blood-2023-185685

Published: 2023

Journal Articles

The Impact of DNMT3A Mutation on Survival of AML Patients Receiving Allogeneic Hematopoietic Cell Transplantation in First Remission Depends on the Karyotype and Co-Occurring Mutations: On Behalf of the EBMT Acute Leukemia Working Party

Iman Abou Dalle, Jacques-Emmanuel Galimard, Xavier Poire, Anne Huynh, Eva Wagner Drouet, David Burns, Jiří Mayer, Nicolaus Kröger, Matthias Eder, Jaime Sanz, Depei Wu, Matthias Stelljes, Mahmoud Aljurf, Arnon Nagler, Jordi Esteve, Fabio Ciceri, Ali Bazarbachi, Mohamad Mohty

Blood (2023) 142 (Supplement 1): 658.

https://doi.org/10.1182/blood-2023-179531

Published: 2023

Journal Articles

Efficacy of CD19-Directed CAR T Cell Therapy in Patients with Primary or Secondary CNS Lymphoma - an Analysis of the EBMT Lymphoma WP and the Gocart Coalition

Blood (2023) 142 (Supplement 1): 1031.

https://doi.org/10.1182/blood-2023-174883

Published: 2023

Journal Articles

Rare germline complement factor H variants in patients with paroxysmal nocturnal hemoglobinuria

Pedro Henrique Prata, Jacques-Emmanuel Galimard, Flore Sicre de Fontbrune, Anna Duval, Paula Vieira Martins, Stephane Roncelin, Pierre-Édouard Debureaux, Anne-Claire Lepretre, Lise Larcher, Rudy Birsen, Ygal Benhamou, Jean Soulier, Gérard Socié, Véronique Fremeaux-Bacchi, Régis Peffault de Latour

Blood (2023) 141 (15): 1812–1816.

https://doi.org/10.1182/blood.2022017019

Published: 2023

Includes: Supplemental data

Journal Articles

Comparison of Fludarabine/Melphalan (FluMel) with Fludarabine/Melphalan/BCNU or Thiotepa (FBM/FTM) in Patients with AML in First Complete Remission Undergoing Allogeneic Hematopoietic Stem Cell Transplantation - a Registry Study on Behalf of the EBMT Acute Leukemia Working Party

Blood (2022) 140 (Supplement 1): 2110–2112.

https://doi.org/10.1182/blood-2022-162277

Published: 2022

Journal Articles

The Impact of Pre-Transplant Extramedullary Disease on the Outcome of Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Children- on Behalf of PDWP/EBMT

Blood (2022) 140 (Supplement 1): 12938–12940.

https://doi.org/10.1182/blood-2022-162484

Published: 2022

Journal Articles

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Congenital Amegakaryocytic Thrombocytopenia, a PDWP/EBMT Study

Blood (2022) 140 (Supplement 1): 10895–10896.

https://doi.org/10.1182/blood-2022-166636

Published: 2022

Journal Articles

Frequency and Impact of Pre-Transplant Somatic Co-Occurring Mutations on Clinical Outcomes of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation: On Behalf of the EBMT Acute Leukemia Working Party

Ali Bazarbachi, Jacques-Emmanuel Galimard, Myriam Labopin, Iman Abou Dalle, Bruno Lioure, Johan A. Maertens, Maija Itälä-Remes, Maria Pilar Gallego Hernanz, Gesine Bug, Josep-Maria Ribera, Alain Gadisseur, Christoph Schmid, Xavier Poiré, Manuel Jurado Chacón, Frederic Baron, Eolia Brissot, Arnon Nagler, Fabio Ciceri, Mohamad Mohty

Blood (2022) 140 (Supplement 1): 735–736.

https://doi.org/10.1182/blood-2022-162162

Published: 2022

Journal Articles

Specific Cytogenetic Abnormalities at Diagnosis Predict Survival after Hematopoietic Cell Transplant in Poor-Risk Pediatric Acute Myeloid Leukemia: A PDWP/EBMT Study

Blood (2022) 140 (Supplement 1): 1882–1884.

https://doi.org/10.1182/blood-2022-162596

Published: 2022

Journal Articles

Impact of Donor and Patient CMV Serology in Children Receiving First Geno-Identical or Unrelated HSCT for Malignant Hematological Disease: An EBMT Retrospective Registry Study

Blood (2022) 140 (Supplement 1): 4718–4720.

https://doi.org/10.1182/blood-2022-164538

Published: 2022

Journal Articles

Outcome of Allogeneic HSCT after Chemo-Based Conditioning in Infants with Acute Myeloid Leukemia in First Complete Remission: A Multicenter EBMT-PDWP Study

Blood (2021) 138 (Supplement 1): 2862.

https://doi.org/10.1182/blood-2021-145858

Published: 2021

Journal Articles

Long-Term Outcome of Peripheral Blood Autologous Stem Cell Transplantation (AutoSCT) for De Novo Acute Myeloid Leukemia in Patients Achieving First Complete Remission after One Vs Two Induction Courses: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Arnon Nagler, Jacques-Emmanuel Galimard, Myriam Labopin, Didier Blaise, William Arcese, Depei Wu, Gwendolyn Van Gorkom, Marie Thérèse Rubio, Tobias Gedde-Dahl, Anne Huynh, Francesco Lanza, Norbert Claude Gorin, Sr., Mohamad Mohty, Silvia Maria Trisolini, Arnaud Pigneux

Blood (2021) 138 (Supplement 1): 1840.

https://doi.org/10.1182/blood-2021-145031

Published: 2021

Journal Articles

Use of Post-Transplant Cyclophosphamide in One-Antigen Mismatched Unrelated Donor Transplantation Results in Similar Transplant Outcomes Than Haploidentical Hransplantation: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the EBMT

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-137099

Published: 2020

Journal Articles

Reduced Intensity Vs. Non-Myeloablative Conditioning Regimens for Haploidentical Transplantation in Complete Remission Acute Myeloid Leukemia: A Study from the ALWP of the EBMT

Raynier Devillier, Jacques-Emmanuel Galimard, Myriam Labopin, MD, Didier Blaise, MD, Emanuele Angelucci, Luca Castagna, Jiri Pavlu, MDMRCP,FRCPath, Gerard Socie, MDPhD, Massimo Martino, Friedrich Stoelzel, PD, MD, Gesine Bug, Yves Chalandon, MD, Benedetto Bruno, MD, Victoria Potter, MBBS, BSc, FRACP, FRCPA, Eolia Brissot, MDPhD, Bipin N. Savani, MD, Arnon Nagler, MD, Mohamad Mohty, MD PhD

Blood (2020) 136 (Supplement 1): 9.

https://doi.org/10.1182/blood-2020-140657

Published: 2020

NARROW

Prognostic Factors Impacting Post-Transplant Outcomes in Adult T-Cell Acute Lymphoblastic Leukemia: A Registry-Based Study By the EBMT Acute Leukemia Working Party

A Multi-Center Retrospective Analysis of Outcomes Post Allogeneic Stem Cell Transplantation in AML Patients with TET2 Mutations: A Study on Behalf of the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

The Impact of DNMT3A Mutation on Survival of AML Patients Receiving Allogeneic Hematopoietic Cell Transplantation in First Remission Depends on the Karyotype and Co-Occurring Mutations: On Behalf of the EBMT Acute Leukemia Working Party

Efficacy of CD19-Directed CAR T Cell Therapy in Patients with Primary or Secondary CNS Lymphoma - an Analysis of the EBMT Lymphoma WP and the Gocart Coalition

Rare germline complement factor H variants in patients with paroxysmal nocturnal hemoglobinuria

Comparison of Fludarabine/Melphalan (FluMel) with Fludarabine/Melphalan/BCNU or Thiotepa (FBM/FTM) in Patients with AML in First Complete Remission Undergoing Allogeneic Hematopoietic Stem Cell Transplantation - a Registry Study on Behalf of the EBMT Acute Leukemia Working Party

The Impact of Pre-Transplant Extramedullary Disease on the Outcome of Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Children- on Behalf of PDWP/EBMT

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Congenital Amegakaryocytic Thrombocytopenia, a PDWP/EBMT Study

Frequency and Impact of Pre-Transplant Somatic Co-Occurring Mutations on Clinical Outcomes of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation: On Behalf of the EBMT Acute Leukemia Working Party

Specific Cytogenetic Abnormalities at Diagnosis Predict Survival after Hematopoietic Cell Transplant in Poor-Risk Pediatric Acute Myeloid Leukemia: A PDWP/EBMT Study

Impact of Donor and Patient CMV Serology in Children Receiving First Geno-Identical or Unrelated HSCT for Malignant Hematological Disease: An EBMT Retrospective Registry Study

Outcome of Allogeneic HSCT after Chemo-Based Conditioning in Infants with Acute Myeloid Leukemia in First Complete Remission: A Multicenter EBMT-PDWP Study

Use of Post-Transplant Cyclophosphamide in One-Antigen Mismatched Unrelated Donor Transplantation Results in Similar Transplant Outcomes Than Haploidentical Hransplantation: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the EBMT

Reduced Intensity Vs. Non-Myeloablative Conditioning Regimens for Haploidentical Transplantation in Complete Remission Acute Myeloid Leukemia: A Study from the ALWP of the EBMT

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only